Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

Article Abstract:

A multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who are randomly assigned to receive 20 mg of atorvastatin per day or matching placebo is presented. The finding indicate that atorvastatin has no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infraction, and stroke in patients with diabetes receiving hemodialysis.

Author: Ritz, Eberhard, Mann, Johannes F.E., Olschewski, Manfred, Wanner, Christoph, Marz, Winfried, Krane, Vera, Ruf, Gunther
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
United Kingdom, Type 2 diabetes, Dosage and administration, Hemodialysis patients, Atorvastatin

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency

Article Abstract:

Benazepril, an angiotensin-converting-enzyme inhibitor, may prevent disease progression in patients with kidney failure. In a three year clinical trial of patients with renal insufficiency from a variety of causes, 300 patients were treated with benazepril and 283 received a placebo. For patients treated with benazepril, reduction of the risk of reaching the primary endpoint of kidney function at three years was 71% for those with mild insufficiency, 46% for those with moderate insufficiency and 53% overall. Although benazepril provided no benefit for patients suffering from polycystic kidney disease, it reduced risk for male patients, patients with glomerular diseases, patients with base-line proteinuria greater than 1g/day, patients with diabetic neuropathies, and patients with insufficiency from unknown causes.

Author: Ritz, Eberhard, Mann, Johannes F.E., Ponticelli, Claudio, Zucchelli, Pietro, Locatelli, Francesco, Maschio, Giuseppe, Alberti, Daniele, Janin, Gerard, Motolese, Mario
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
Evaluation, ACE inhibitors, Angiotensin converting enzyme inhibitors, Antihypertensive drugs, Antihypertensive agents, Chronic kidney failure

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Health aspects, Drug therapy
Similar abstracts:
  • Abstracts: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
  • Abstracts: Effect of oral iodized oil on thyroid size and thyroid hormone metabolism in children with concurrent selenium and iodine deficiency
  • Abstracts: Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infraction. Amiodarone to prevent recurrence of atrial fibrillation
  • Abstracts: Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study
  • Abstracts: Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.